Pharma Stocks Fall After U.S. Drug Price Reduction Plans
Indian pharmaceutical stocks saw a significant dip on May 12, 2025, following the announcement by U.S. President Donald Trump regarding plans to reduce prescription drug prices by up to 80%. The executive order, which introduces a “most favored nation” approach, aims to ensure the U.S. will not pay more for drugs than the lowest price paid by other countries. This move has led to concerns within the global pharma market, particularly affecting Indian companies with large stakes in the U.S. pharmaceutical market.
Impact on Indian Pharma Companies
Indian pharmaceutical stocks took a hit, as many of these companies rely heavily on U.S. sales for their revenue. Shares of key players such as Sun Pharmaceutical Industries Ltd. dropped 7%, while Lupin Ltd. and Aurobindo Pharma Ltd. saw declines of around 3%. The Nifty Pharma index also fell by 2.3%, reflecting the broader impact on India’s pharmaceutical sector.
Global Pharma Market Response
The U.S. move also rattled global pharmaceutical markets. Major American drug manufacturers such as AbbVie, Amgen, Pfizer, Eli Lilly, and Merck reported declines in premarket trading, falling between 2.1% and 3.6%. In Europe, companies like AstraZeneca, GSK, and Roche saw their shares drop by 3.3% to 6.8%, and pharmaceutical stocks across Asia and Australia followed a similar downward trend.
Also Read: India–UK Free Trade Agreement Finalized: A Game-Changer for Bilateral Trade
Uncertainties Over Implementation
While the U.S. executive order is expected to be signed shortly, there is still much uncertainty surrounding its specifics. Questions remain regarding whether it will affect government-run health programs like Medicare and Medicaid, and how it will influence pricing for different types of drugs, including generics and specialty medications.
Outlook
The announcement has introduced a layer of uncertainty in the pharmaceutical industry, especially for Indian companies with heavy exposure to the U.S. market. Investors are closely watching how the situation develops and its potential long-term effects on both Indian and global pharmaceutical markets.
Share
You may also like
Summary
Read Full
open_in_newChinese AI startup DeepSeek is making waves in the global artificial intelligence race, emerging as a credible challenger to the long-standing dominance of American tech giants like OpenAI, Anthropic, and Google DeepMind. Backed by substantial local investment and supported by China's broader push for technological self-reliance, DeepSeek's rapid evolution signals a pivotal shift in the AI arms race.
Summary
Read Full
open_in_newThe 2025 Met Gala has made history, raising a record-breaking $31 million for the Metropolitan Museum of Art’s Costume Institute. With an awe-inspiring guest list, bold fashion statements, and a unifying theme celebrating cultural fusion, the night proved that the Met Gala remains fashion’s most powerful fundraising force.
Summary
Read Full
open_in_newFaced with stringent U.S. export restrictions, Chinese technology giants are shifting their AI development strategies away from dependence on NVIDIA. In response, these companies are ramping up domestic innovation, forming strategic alliances, and exploring new chip solutions to remain competitive in the global AI race.
Walmart Launches AI-Powered "Everyday Health Signals" to Promote Better Eating
Summary
Read Full
open_in_newWalmart has launched "Everyday Health Signals," an AI-powered platform offering personalized nutrition advice to help customers make healthier grocery choices.
Summary
Read Full
open_in_newNVIDIA and AMD are set to release customized AI chips for China, aligning with U.S. export restrictions while maintaining their presence in a key global market.
US Stock Futures Steady Ahead of Nvidia Earnings Report
Summary
Read Full
open_in_newUS stock futures remained flat today as investors await Nvidia’s quarterly earnings report. The chipmaker's performance is seen as a key indicator of tech sector momentum, particularly in the booming AI space.
Post a comment
Comments
Most Popular
Categories
